Search

Brenda Libby Coleman

Examiner (ID: 13884, Phone: (571)272-0665 , Office: P/1624 )

Most Active Art Unit
1624
Art Unit(s)
1202, 2611, 1624, 1611
Total Applications
3154
Issued Applications
1967
Pending Applications
488
Abandoned Applications
741

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18444491 [patent_doc_number] => 11680049 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-20 [patent_title] => Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors [patent_app_type] => utility [patent_app_number] => 17/946024 [patent_app_country] => US [patent_app_date] => 2022-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 26373 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17946024 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/946024
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Sep 14, 2022 Issued
Array ( [id] => 18162134 [patent_doc_number] => 20230028726 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/942121 [patent_app_country] => US [patent_app_date] => 2022-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942121 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/942121
Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Sep 9, 2022 Issued
Array ( [id] => 18384456 [patent_doc_number] => 11655224 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors [patent_app_type] => utility [patent_app_number] => 17/942122 [patent_app_country] => US [patent_app_date] => 2022-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 26379 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942122 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/942122
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Sep 9, 2022 Issued
Array ( [id] => 18166967 [patent_doc_number] => 20230033573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/942123 [patent_app_country] => US [patent_app_date] => 2022-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942123 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/942123
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Sep 9, 2022 Issued
Array ( [id] => 18384454 [patent_doc_number] => 11655222 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors [patent_app_type] => utility [patent_app_number] => 17/942120 [patent_app_country] => US [patent_app_date] => 2022-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 26370 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942120 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/942120
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Sep 9, 2022 Issued
Array ( [id] => 18428661 [patent_doc_number] => 11673871 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors [patent_app_type] => utility [patent_app_number] => 17/942112 [patent_app_country] => US [patent_app_date] => 2022-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 26358 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942112 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/942112
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Sep 9, 2022 Issued
Array ( [id] => 18384453 [patent_doc_number] => 11655221 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-23 [patent_title] => Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors [patent_app_type] => utility [patent_app_number] => 17/942106 [patent_app_country] => US [patent_app_date] => 2022-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 26386 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942106 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/942106
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Sep 8, 2022 Issued
Array ( [id] => 18612237 [patent_doc_number] => 20230278969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/942111 [patent_app_country] => US [patent_app_date] => 2022-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26606 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942111 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/942111
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Sep 8, 2022 Issued
Array ( [id] => 18375912 [patent_doc_number] => 20230150993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => ANTIPROLIFERATION COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/930352 [patent_app_country] => US [patent_app_date] => 2022-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99001 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930352 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/930352
Antiproliferation compounds and uses thereof Sep 6, 2022 Issued
Array ( [id] => 19504943 [patent_doc_number] => 12116354 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-15 [patent_title] => RIP1 inhibitory compounds and methods for making and using the same [patent_app_type] => utility [patent_app_number] => 17/939020 [patent_app_country] => US [patent_app_date] => 2022-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28710 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 271 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17939020 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/939020
RIP1 inhibitory compounds and methods for making and using the same Sep 6, 2022 Issued
Array ( [id] => 19274391 [patent_doc_number] => 12024502 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-02 [patent_title] => Biased adrenergic agonists [patent_app_type] => utility [patent_app_number] => 17/902085 [patent_app_country] => US [patent_app_date] => 2022-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 29 [patent_no_of_words] => 12268 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17902085 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/902085
Biased adrenergic agonists Sep 1, 2022 Issued
Array ( [id] => 18420007 [patent_doc_number] => 20230174468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => SULFATED PILLARARENES, METHODS OF MAKING SAME, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/822863 [patent_app_country] => US [patent_app_date] => 2022-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17822863 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/822863
SULFATED PILLARARENES, METHODS OF MAKING SAME, AND USES THEREOF Aug 28, 2022 Pending
Array ( [id] => 18886355 [patent_doc_number] => 11865111 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Antiviral drugs targeting the N-terminal domain (NTD) of the coronavirus spike receptor binding domain (RBD) [patent_app_type] => utility [patent_app_number] => 17/819178 [patent_app_country] => US [patent_app_date] => 2022-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 2752 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17819178 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/819178
Antiviral drugs targeting the N-terminal domain (NTD) of the coronavirus spike receptor binding domain (RBD) Aug 10, 2022 Issued
Array ( [id] => 18208197 [patent_doc_number] => 20230054455 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND THEIR USES [patent_app_type] => utility [patent_app_number] => 17/882707 [patent_app_country] => US [patent_app_date] => 2022-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17882707 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/882707
Controlled release formulations of riluzole and their uses Aug 7, 2022 Issued
Array ( [id] => 18909249 [patent_doc_number] => 11872212 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => Self-healing organic crystals [patent_app_type] => utility [patent_app_number] => 17/873246 [patent_app_country] => US [patent_app_date] => 2022-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 5418 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17873246 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/873246
Self-healing organic crystals Jul 25, 2022 Issued
Array ( [id] => 18229130 [patent_doc_number] => 20230068124 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate [patent_app_type] => utility [patent_app_number] => 17/874122 [patent_app_country] => US [patent_app_date] => 2022-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49811 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17874122 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/874122
Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate Jul 25, 2022 Abandoned
Array ( [id] => 18391337 [patent_doc_number] => 20230159555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS [patent_app_type] => utility [patent_app_number] => 17/814115 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 189590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814115 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/814115
SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS Jul 20, 2022 Pending
Array ( [id] => 18420036 [patent_doc_number] => 20230174497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => RHEIN AMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF, AND INHIBITOR OF HEPATOCELLULAR CARCINOMA (HCC) WITH SPECIFIC RECQL4 EXPRESSION [patent_app_type] => utility [patent_app_number] => 17/811201 [patent_app_country] => US [patent_app_date] => 2022-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5861 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811201 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/811201
RHEIN AMIDE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF, AND INHIBITOR OF HEPATOCELLULAR CARCINOMA (HCC) WITH SPECIFIC RECQL4 EXPRESSION Jul 6, 2022 Abandoned
Array ( [id] => 18272007 [patent_doc_number] => 20230093249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => ANTI-VIRAL COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/811008 [patent_app_country] => US [patent_app_date] => 2022-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 104094 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811008 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/811008
Anti-viral compounds Jul 5, 2022 Issued
Array ( [id] => 19290402 [patent_doc_number] => 12029741 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-07-09 [patent_title] => 5 beta dihydrotestosterone pharmaceutical formulations and related methods [patent_app_type] => utility [patent_app_number] => 17/853497 [patent_app_country] => US [patent_app_date] => 2022-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 19589 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17853497 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/853497
5 beta dihydrotestosterone pharmaceutical formulations and related methods Jun 28, 2022 Issued
Menu